{"protocolSection":{"identificationModule":{"nctId":"NCT00446641","orgStudyIdInfo":{"id":"ARCC"},"organization":{"fullName":"Asan Medical Center","class":"OTHER"},"briefTitle":"Overcome Biochemical Aspirin Resistance Through Cilostazol Combination","officialTitle":"Phase 4 Study of Additional Cilostazol for Overcoming Biochemical Aspirin Resistance in the Chronic Stroke Patients","acronym":"ARCC"},"statusModule":{"statusVerifiedDate":"2009-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-03"},"primaryCompletionDateStruct":{"date":"2008-06","type":"ACTUAL"},"completionDateStruct":{"date":"2008-07","type":"ACTUAL"},"studyFirstSubmitDate":"2007-03-12","studyFirstSubmitQcDate":"2007-03-12","studyFirstPostDateStruct":{"date":"2007-03-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-01-22","resultsFirstSubmitQcDate":"2009-12-10","resultsFirstPostDateStruct":{"date":"2010-01-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2009-12-10","lastUpdatePostDateStruct":{"date":"2010-01-18","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Sun U. Kwon","oldOrganization":"Asan Medical Center"},"leadSponsor":{"name":"Asan Medical Center","class":"OTHER"},"collaborators":[{"name":"Korea Otsuka Pharmaceutical Co., Ltd.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study will recruit 316 ischemic stroke patients taking aspirin.\n\nThey will be randomly assigned into cilostazol group or placebo group. Every patients will take 200mg of cilostazol a day or placebo for 1 month.\n\nThe primary outcome variable of this study is rate of biochemical aspirin resistance on the Ultra Rapid Platelet Function Assay-ASA.","detailedDescription":"\\[Goal\\] To reveal the effect and safety of additional cilostazol for overcoming biochemical aspirin resistance.\n\n\\[Trial Design\\] Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial\n\n\\[Participants\\] Ischemic stroke patients taking aspirin\n\n\\[Methods\\]\n\n* Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial\n* Investigational product: Cilostazol 200mg (100mg twice per day)\n* Concomitant medication: Aspirin 100 mg per day\n* Medication Duration: 1 month\n\n\\[Outcome Variables\\]\n\nPrimary Outcome Variable:\n\n• the proportion of patients with aspirin reaction units (ARUs) values ≥550 on the Ultra Rapid Platelet Function Assay-ASA\n\nSecondary outcome variables:\n\n* the proportion of patients with ARUs values ≥500 on the Ultra Rapid Platelet Function Assay-ASA\n* ARUs values\n* Bleeding time (BT)\n* Fatal or major bleeding complications\n* Any bleeding complications"},"conditionsModule":{"conditions":["Cerebral Infarction"],"keywords":["Infarction, Cerebral","Cilostazol","Aspirin Resistance"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":244,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1 Cilostazol","type":"EXPERIMENTAL","description":"100mg of Cilostazol twice a day","interventionNames":["Drug: Cilostazol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"matching placebo to cilostazol","interventionNames":["Drug: placebo"]}],"interventions":[{"type":"DRUG","name":"Cilostazol","description":"cilostazol 100mg twice a day for 4 weeks","armGroupLabels":["1 Cilostazol"],"otherNames":["pletaal"]},{"type":"DRUG","name":"placebo","description":"placebo 1 tablet twice a day matching for cilostazol","armGroupLabels":["Placebo"],"otherNames":["matching placebo of cilostazol"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Aspirin Resistance (ARU ≥ 550)","description":"The number of patients with aspirin reaction units (ARUs) values ≥ 550 on the Ultra Rapid Platelet Function Assay-ASA among the recruited patients","timeFrame":"4 weeks after treatment"}],"secondaryOutcomes":[{"measure":"Aspirin Resistance (ARU ≥ 500)","description":"The number of participants with ARUs values ≥500 on the Ultra Rapid Platelet Function Assay-ASA; ARUs values","timeFrame":"4 weeks after reatment"},{"measure":"Bleeding Time (BT)","description":"for evaluation of the extent of the bleeding time prolongation by additional cilostazol","timeFrame":"4 weeks after reatment"},{"measure":"Fatal or Major Bleeding Complications;","description":"Fatal or life-threatening bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood","timeFrame":"events ocurred during study medication after randomization"},{"measure":"Any Bleeding Complications","description":"any bleeding events causing medical attention","timeFrame":"events ocurred during study medication after randomization"},{"measure":"Difference of Post-treatment ARU and Baseline ARU","description":"summation of change of ARU (posttreatment ARU - baseline ARU) of individual patients","timeFrame":"baseline ARU measured at the randomization and post-treatment ARU measured at the 4weeks treatment with study medication"},{"measure":"Post-treatment ARU","description":"mean of ARU value of individual participants after 4 weeks treatment","timeFrame":"after 4 weeks treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Symptomatic cerebral infarction documented on MRI or CT\n* More than 35 years of age\n* Patients taking aspirin 100mg a day for 2 weeks or more before randomization\n\nExclusion Criteria:\n\n* Patients taking any antiplatelets other than aspirin within 2 weeks before randomization\n* Patients taking any anticoagulants within 2 weeks before randomization\n* Patients taking thrombolytic therapy within 2 weeks before randomization\n* Patients taking any NSAIDs within 2 weeks before randomization\n* Patients who need to take NSAIDs regularly (e.g. rheumatic arthritis).\n* Bleeding diathesis\n* Chronic liver disease (ALT \\> 100 or AST \\> 100) or chronic renal disease (creatinine \\> 3.0mg/dl)\n* Anemia (hemoglobin \\< 10mg/dl) or thrombocytopenia (platelet count less than 100,000/mm3)\n* Pregnant or lactating patients\n* Patients scheduled for angioplasty or revascularization procedures within 4 weeks\n* Patients scheduled for any surgery or invasive procedures within 4 weeks\n* Patients having acute coronary syndrome","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Sun U Kwon, MD. PhD.","affiliation":"Asan Medical Center, Univsersity of Ulsan, Medical College","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Jae-Kwan Cha","city":"Busan","zip":"602-715","country":"Korea, Republic of","geoPoint":{"lat":35.10278,"lon":129.04028}},{"facility":"Eulji University Hospital","city":"Daejon","zip":"302-799","country":"Korea, Republic of"},{"facility":"Kangdong Sacred Heart Hospital, Hallym University","city":"Seoul","zip":"134-701","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center","city":"Seoul","zip":"138-736","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Patients with aspirin therapy were recruited due to subacute or chronic ischemic stroke.\n\nThe patients should have taken aspirin 100mg per day at least 2 weeks before randomization","recruitmentDetails":"244 patients with subacute or chronic ischemic stroke were recruited from outpatient clinics of 5 comprehensive stroke centers of Korea","groups":[{"id":"FG000","title":"Cilostazol","description":"Cilostazol 100mg twice per day"},{"id":"FG001","title":"Placebo","description":"matching placebo to cilostazol"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"125"},{"groupId":"FG001","numSubjects":"119"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"108"},{"groupId":"FG001","numSubjects":"109"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"10"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"poor compliance","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cilostazol","description":"Cilostazol 100mg twice per day"},{"id":"BG001","title":"Placebo","description":"matching placebo to cilostazol"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"244"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"146"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"98"}]}]}]},{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.24","spread":"10.198"},{"groupId":"BG001","value":"62.83","spread":"9.963"},{"groupId":"BG002","value":"62.02","spread":"10.095"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"77"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"78"},{"groupId":"BG002","value":"167"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Korea, Republic of","categories":[{"measurements":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"244"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Aspirin Resistance (ARU ≥ 550)","description":"The number of patients with aspirin reaction units (ARUs) values ≥ 550 on the Ultra Rapid Platelet Function Assay-ASA among the recruited patients","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"4 weeks after treatment","groups":[{"id":"OG000","title":"Cilostazol","description":"Cilostazol 100mg twice per day"},{"id":"OG001","title":"Placebo","description":"matching placebo to cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"We assumed that the prevalence of AR would be 12 % among ischemic stroke patients who were treated with aspirin 100 per day. The prevalence could be reduced to 4% with additional cilostazol therapy","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.654","statisticalMethod":"Chi-squared","paramType":"Odds Ratio (OR)","paramValue":"0.82","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Aspirin Resistance (ARU ≥ 500)","description":"The number of participants with ARUs values ≥500 on the Ultra Rapid Platelet Function Assay-ASA; ARUs values","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"4 weeks after reatment","groups":[{"id":"OG000","title":"Cilostazol","description":"Cilostazol 100mg twice per day"},{"id":"OG001","title":"Placebo","description":"matching placebo to cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"28"}]}]}]},{"type":"SECONDARY","title":"Bleeding Time (BT)","description":"for evaluation of the extent of the bleeding time prolongation by additional cilostazol","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"seconds","timeFrame":"4 weeks after reatment","groups":[{"id":"OG000","title":"Cilostazol","description":"Cilostazol 100mg twice per day"},{"id":"OG001","title":"Placebo","description":"matching placebo to cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":"38.5"},{"groupId":"OG001","value":"106","spread":"34.2"}]}]}]},{"type":"SECONDARY","title":"Fatal or Major Bleeding Complications;","description":"Fatal or life-threatening bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"events ocurred during study medication after randomization","groups":[{"id":"OG000","title":"Cilostazol","description":"Cilostazol 100mg twice per day"},{"id":"OG001","title":"Placebo","description":"matching placebo to cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Any Bleeding Complications","description":"any bleeding events causing medical attention","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"events ocurred during study medication after randomization","groups":[{"id":"OG000","title":"Cilostazol","description":"Cilostazol 100mg twice per day"},{"id":"OG001","title":"Placebo","description":"matching placebo to cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Difference of Post-treatment ARU and Baseline ARU","description":"summation of change of ARU (posttreatment ARU - baseline ARU) of individual patients","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"change of ARU measured","timeFrame":"baseline ARU measured at the randomization and post-treatment ARU measured at the 4weeks treatment with study medication","groups":[{"id":"OG000","title":"Cilostazol","description":"Cilostazol 100mg twice per day"},{"id":"OG001","title":"Placebo","description":"matching placebo to cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.8","spread":"77.6"},{"groupId":"OG001","value":"12.1","spread":"71.1"}]}]}]},{"type":"SECONDARY","title":"Post-treatment ARU","description":"mean of ARU value of individual participants after 4 weeks treatment","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ARU","timeFrame":"after 4 weeks treatment","groups":[{"id":"OG000","title":"Cilostazol","description":"Cilostazol 100mg twice per day"},{"id":"OG001","title":"Placebo","description":"matching placebo to cilostazol"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"454.8","spread":"52.8"},{"groupId":"OG001","value":"473.6","spread":"63.9"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","eventGroups":[{"id":"EG000","title":"Cilostazol","description":"Cilostazol 100mg twice per day","seriousNumAffected":0,"seriousNumAtRisk":125,"otherNumAffected":7,"otherNumAtRisk":125},{"id":"EG001","title":"Placebo","description":"matching placebo to cilostazol","seriousNumAffected":0,"seriousNumAtRisk":119,"otherNumAffected":2,"otherNumAtRisk":119}],"otherEvents":[{"term":"headache","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":125},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":119}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Professor Sun U. Kwon","organization":"Asan Medical Center, University of Ulsan College of Medicine","email":"sukwon@amc.seoul.kr","phone":"82-2-3010-3960"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007238","term":"Infarction"}],"ancestors":[{"id":"D000007511","term":"Ischemia"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000020521","term":"Stroke"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Infarction","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077407","term":"Cilostazol"}],"ancestors":[{"id":"D000001993","term":"Bronchodilator Agents"},{"id":"D000001337","term":"Autonomic Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018927","term":"Anti-Asthmatic Agents"},{"id":"D000019141","term":"Respiratory System Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000014665","term":"Vasodilator Agents"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000058987","term":"Phosphodiesterase 3 Inhibitors"},{"id":"D000010726","term":"Phosphodiesterase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","relevance":"LOW"},{"id":"M1788","name":"Cilostazol","asFound":"Stored","relevance":"HIGH"},{"id":"M4959","name":"Bronchodilator Agents","relevance":"LOW"},{"id":"M20653","name":"Anti-Asthmatic Agents","relevance":"LOW"},{"id":"M20827","name":"Respiratory System Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M17102","name":"Vasodilator Agents","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"M29023","name":"Phosphodiesterase 3 Inhibitors","relevance":"LOW"},{"id":"M13319","name":"Phosphodiesterase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"},{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"Resp","name":"Respiratory System Agents"}]}},"hasResults":true}